Skip to content

Study to check Efficacy of Camel Milk Powder in height growth, immunity and gut health Improvement in children between 05 to 16 years of Age

A Prospective,Randomized,Two-arm,Open label study to evaluate Efficacy of Camel Milk Powder Formulation in height growth, immunity and gut health Improvement in children between 05 to 16 years of Age

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/05/042515
Enrollment
51
Registered
2022-05-12
Start date
Unknown
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Camel milk powder formulation: Day 1 to Day 7 : 50 mL twice a day (100 mL/day) Day 8 till Month 6 : 100 mL twice a day (200 mL/day) Control Intervention1: Not applicable: Not applicabl

Sponsors

Aadvik Foods Products Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Children of either gender between 5 to 16 Years of age. 2) Children of height less than 97 percentile as per the Indian Academy of Paediatrics (IAP) growth charts, 2015. 3) Children (if applicable) and their parents who can understand and are willing to provide the appropriate consent.

Exclusion criteria

Exclusion criteria: 1) Children diagnosed with growth disorders like Marasmus and kwashiorkor. 2) Children currently suffering from abdominal pain and intestinal discomfort accompanied by vomiting and diarrhoea at the time of consent. 3) Children suffering from any chronic diseases or any diagnosis, as per the discretion of the investigator, which may jeopardize the study assessments or outcome.

Design outcomes

Primary

MeasureTime frame
Change in height by using Stadiometer or an Anthropometer from baseline to EoS [Timeframe: Visit 1 to Visit 4]Timepoint: 168 days

Secondary

MeasureTime frame
1) Anthropometric measurement (weight, waist circumference and hip circumference), from baseline to EoS [Timeframe: Visit 1 to Visit 4] 2) Change in appetite and activity levels from baseline to EoS [Timeframe: Visit 1 to Visit 4] 3) Incidence and frequency of diarrhoea and vomiting from baseline to EoS [Timeframe: Visit 1 to Visit 4] 4) Incidence and duration of sick episodes from baseline to EoS [Timeframe: Visit 1 to Visit 4] 5) Adverse events reported after the consumption of the study product from baseline to EoS [Timeframe: Visit 1 to Visit 4]Timepoint: 168 days

Countries

India

Contacts

Public ContactMr Vairamuthu Ammaiyappan

iDD Research Solutions INC

yogesh@iddresearch.com9717832255

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026